Allied Minds Backs Precision Biopsy

Boston-based investment firm Allied Minds has founded a new medical device company, Precision Biopsy, in cooperation with the University of Colorado. The new firm is developing an “optical” biopsy needle for diagnosing prostate cancer; the device uses spectroscopy to differentiate between normal and malignant tissue in real-time. Allied Minds specializes in very early-stage investments in projects spun out of academia.

Author: Erik Mellgren

Erik Mellgren is a Swedish journalist who worked for Xconomy Boston in 2008 as part of the Stanford Innovation Journalism Fellowship program. He is a 26-year veteran of Ny Teknik, a leading technology and innovation magazine in Sweden.